Lorfast

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lorfast

Property Description
Active ingredient Loratadine (INN)
Form Tablets, Oral Solution/Syrup
Pharmacological class Second-generation H1-receptor Antagonist
Common use Symptomatic relief of allergy manifestations
Origin Synthetic (tricyclic derivative)

What Type of Medicine is Lorfast (Loratadine)?

Lorfast is a medication defined by its active ingredient, Loratadine, which is classified as a second-generation Histamine H1-receptor Antagonist. The medicine is a synthetic tricyclic derivative, a key chemical characteristic that differentiates it from older allergy treatments.

This classification reflects the drug’s highly selective mechanism of action, making it a well-recognized agent for allergy management. Loratadine is recognized as an essential medicine, confirming its global therapeutic relevance.

Composition and Available Forms of Lorfast

The singular active component in Lorfast is Loratadine. This medicine is designed for the oral route of administration and is consistently available as a single-active-ingredient product. The primary dosage forms include solid preparations, such as tablets, and oral liquid preparations, including syrup or solution. The liquid formulations are particularly useful for patient groups who have difficulty swallowing tablets, ensuring flexible administration.

The Loratadine compound maintains its effectiveness over a full 24-hour period, which facilitates a convenient once-daily dosing regimen.

General Purpose and Unique Benefit

The general purpose of Lorfast is to mitigate the external and internal symptoms that arise from allergic responses, such as sneezing, watery eyes, and itching. This is achieved through the drug’s distinct non-sedating property.

The non-sedating benefit is due to the drug’s molecular structure, which limits its ability to cross the blood-brain barrier. This characteristic allows for effective control of symptoms while minimizing the risk of drowsiness, allowing patients to maintain focus during daily activities.

Regulatory References

  1. Loratadine - Second-Generation H1 Antihistamine Classification (NIH/NCBI)
  2. Loratadine on WHO Model List of Essential Medicines (eEML)
  3. Loratadine Dosage Forms and Administration (NIH/NCBI)

What side effects are possible with Lorfast?

Possible Side Effects and Safety Information

The official regulatory safety profile for Lorfast (Loratadine) is structured based on frequency classifications derived from clinical trials and post-marketing experience. Adverse reactions are grouped by the physiological system they affect, as defined in regulatory documents like the Summary of Product Characteristics (SmPC) and FDA Prescribing Information.

Common Adverse Reactions

The most frequently reported adverse events are classified as Common (ge 1/100 to < 1/10) and primarily involve the Nervous System and general conditions. These typically include headache, somnolence (drowsiness), fatigue, and dry mouth. In the paediatric population, common side effects reported in excess of placebo include headache, nervousness, and fatigue.

Serious and Rare Adverse Reactions

Adverse reactions classified as Very Rare (< 1/10,000) or those reported post-marketing include events associated with the Cardiac, Immune, and Hepatobiliary Systems. These serious reports include hypersensitivity reactions (such as anaphylaxis and angioedema), palpitations, tachycardia, and abnormal hepatic function.

Safety Considerations

The safety documentation notes specific considerations for certain patient groups. Caution is recommended for individuals with severe hepatic impairment, as reduced clearance of Loratadine may occur. Loratadine is generally not recommended during pregnancy or lactation. A specific administration-agnostic safety note requires that the use of this medicine must be discontinued at least 48 hours prior to conducting skin allergy tests, as the substance can interfere with the results.

Overdose and Emergency Response

The official regulatory documentation for Loratadine defines the clinical presentation of overdosage and the subsequent mandated emergency response. Individuals must seek immediate medical help or contact a Poison Control Center right away in all cases of suspected overdosage. Calling emergency services immediately is mandated if the person exhibits severe manifestations, such as collapse, seizures, or trouble breathing.

The most consistently documented clinical signs of overdosage in adults include somnolence (drowsiness), tachycardia (rapid heartbeat), and headache. Overdosage is also reported to increase the occurrence of anticholinergic symptoms. In children who have ingested large quantities of Loratadine syrup, the regulatory summaries note specific reports of extrapyramidal signs and palpitations.

Management is strictly limited to symptomatic and supportive measures. Regulatory documents explicitly state that no specific antidote is known for Loratadine and confirm that the compound is not removed by haemodialysis. Medical procedures such as gastric lavage and the administration of activated charcoal may be considered by healthcare providers as part of the initial emergency protocol. Continued medical monitoring of the patient is required following any initial intervention.

Therapeutic Uses of Lorfast

What Lorfast Treats: Main Uses and Benefits

Lorfast is applied across domains where additional symptomatic support is needed for allergic reactions, generally used to help manage symptoms that interfere with daily functioning. The medicine is commonly used for conditions characterized by periods of heightened symptoms, including allergic rhinitis (seasonal and perennial) and Chronic Idiopathic Urticaria (hives).


Key Therapeutic Focus

The medication is applied in addressing symptom clusters that may become intense or disruptive, such as frequent sneezing, persistent runny nose (rhinorrhea), ocular itching, and intense skin pruritus associated with welts. This contributes to easing the overall symptom load and offers symptomatic relief that supports patients during episodes of heightened discomfort.

“Lorfast is considered relevant for supporting a sense of stability when symptoms are more noticeable, providing supportive relief when symptoms interfere with routine activities.”

A core patient benefit is that the medication is relevant for sustained symptomatic management for a full day, which may assist with maintaining functional stability.


Quick Fact: Relief for Itching

Quick Fact: Relief for Itching

The medication is relevant for easing challenging symptoms associated with both respiratory allergies (itchy nose, throat, and eyes) and allergic skin conditions, specifically the intense pruritus that accompanies chronic hives.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Lorfast (Loratadine)

This information reflects regulatory criteria that define who is eligible to use Loratadine, strictly based on authoritative government documentation. It is not medical advice.

Eligibility Status Key Regulatory Criteria
Absolute Contraindications Patients with a known hypersensitivity or allergy to loratadine, its active metabolite desloratadine, or any ingredient in the formulation. Certain formulations are contraindicated in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
Age Restrictions Use is not recommended or not established in children under 2 years of age due to insufficient safety and efficacy data. The drug is generally approved for adults and children aged 2 years and older, with dosage varying by age and weight.
Physiological Restrictions Patients with severe liver impairment or severe renal insufficiency (Glomerular Filtration Rate < 30 mL/min) are eligible only for restricted use, requiring a lower initial dose (e.g., every other day) due to reduced drug clearance.
Reproductive Status Use is not recommended during pregnancy as a precautionary measure. It is also not recommended or prohibited for women who are breastfeeding, as loratadine and its active metabolite are excreted into breast milk.

The eligibility profile is strictly governed by these factors, defining non-eligible populations (allergies, certain infants) and restricted populations (severe organ impairment) to minimize risk associated with the drug's metabolism and clearance.

What should I know about interactions with other medicines?

Lorfast (loratadine) is generally associated with minimal risk of clinically significant drug interactions. However, its metabolism in the liver by the Cytochrome P450 enzymes (specifically CYP3A4 and CYP2D6) means that other medications affecting these enzymes can alter the concentration of Lorfast in the body.

Increased Lorfast levels may enhance the risk of side effects, although this has typically not led to changes in the overall safety profile in clinical trials.

Reported Drug Interactions

Tell your healthcare provider if you are taking any of the following medicines, as their concurrent use may increase Lorfast plasma concentration:

Drug Class Examples Potential Effect
Antifungal Ketoconazole May elevate Lorfast levels
Antibiotic Erythromycin, Clarithromycin May elevate Lorfast levels
H2-Receptor Antagonist Cimetidine May elevate Lorfast levels

Other Potential Interactions

  • Other Sedatives/CNS Depressants: Although Lorfast is considered non-sedating, co-administration with other medications that cause drowsiness (e.g., alcohol, certain anxiety medications, or prescription painkillers) should be done with caution, as additive effects are possible.
  • Alcohol: Studies indicate that Lorfast does not potentiate the effects of alcohol on psychomotor performance. However, some healthcare professionals advise caution.
  • Skin Allergy Tests: Lorfast should be discontinued several days (typically 2 to 4 days) before any scheduled skin prick or allergy testing, as antihistamines can interfere with the test results.

Mechanism of Action

How Lorfast Works


Targeted Blockade of Peripheral H1 Receptors

This medication and its primary active form function as inverse agonists to selectively block peripheral histamine H1 receptors throughout the body. By stabilizing these receptors in an inactive state, the drug prevents histamine, a key chemical messenger, from binding and initiating the signaling cascade that normally follows H1-receptor activation . This action constitutes the drug's primary mechanism of action.


Modulating Vascular and Nerve Responses

The H1-receptor blockade modifies physiological responses in two key systems: the microvasculature (small blood vessels) and peripheral sensory nerves. By interrupting the histamine signal, the drug reduces the histamine-induced increase in blood vessel wall permeability, which alters the flow of fluid into surrounding tissues. This targeted pathway interference also reduces the transmission of signals from peripheral sensory nerve endings, leading to an alteration in local physiological activity within affected peripheral systems.


Sustained Mechanism via Active Metabolite

The compound is metabolized by the body into desloratadine, which is also an effective, active H1-receptor blocker. This dual-compound mechanism, where both the parent drug and its metabolite are active, extends the duration of receptor blockade. This process ensures the continuous interruption of histamine-mediated signaling, leading to prolonged modulation of histamine-mediated physiological activity.

Dosage and Administration Information

Loratadine (Lorfast) is administered exclusively by the oral route for symptomatic management of allergy manifestations. The administration pattern is standardized to a once-daily schedule due to the drug's sustained 24-hour activity. For most adults and children aged 6 years and older, the standard dose is 10 mg taken once every 24 hours. For younger children between 2 and 5 years, the standard daily dose is 5 mg.

The medicine may be consumed with or without food as the time of intake relative to meals does not affect the standard usage parameters. Dosing adjustments are typically applied for patients with compromised organ function; specifically, for adults and children over 6 years with severe hepatic or renal impairment (creatinine clearance < 30 mL/min), the application is 10 mg every other day.

Administration of the liquid solution requires using a calibrated measuring device to ensure accurate volume is given. If a dose is missed, the standard approach is to take it when remembered, while then resuming the standard daily schedule without taking a double dose. Furthermore, administration of Loratadine is discontinued at least 48 hours before diagnostic allergy skin testing is performed to avoid potential interference with the results.

Recent Clinical Evidence

Research evidence / Overview of studies for Lorfast

Evidence for use in Major Depressive Disorder (MDD)

Lorfast was studied for use in adults experiencing Major Depressive Disorder, a condition characterized by fluctuating or episodic manifestations. The primary research explored short-term symptom changes through controlled trials. These studies monitored outcomes reflecting daily functioning or activity level and measured how symptoms evolved in the observed populations over typical periods of six to eight weeks. Research examined individuals with moderate to severe symptoms, including participants identified as treatment-resistant by researchers. The findings describe patterns observed in the studies related to changes measured on standardized rating scales. Research provides insight into short-term changes in symptom patterns for the specific groups that was evaluated in these initial trials. Long-term outcomes are not well characterized; there is limited information for long-term outcomes or how patterns might persist over many months or years.

Evidence for use in Generalized Anxiety Disorder (GAD)

Research was evaluated in settings involving Generalized Anxiety Disorder, a condition involving periods of heightened symptoms. The evidence primarily stems from short-term, placebo-controlled trials, along with data gathered from observational settings evaluating daily-life functioning. Researchers studied for GAD by measuring patient-reported outcomes describing perceived discomfort and tracking worry and anxiety symptoms. In these trials, research highlights changes measured during the study period in anxiety scale scores. The data show patterns related to symptom measurement in the specific adult populations that participated. Evidence is limited regarding the use of Lorfast in older adults. Furthermore, evidence quality varies across studies, and the extent of comparative evidence is limited for many different subgroups, meaning the findings describe group patterns, not personal outcomes.

What is still uncertain about Lorfast

This section synthesizes the main gaps and limitations in the existing research. Evidence quality varies across studies. Inconsistency in reported findings was observed in some studies. The extent of comparative evidence is limited in many areas. There is limited information for sustained functional outcomes across all indications, as long-term effects are not fully established. Subgroup findings are uncertain, as data for specific patient characteristics remain insufficient. Overall, the evidence highlights what is known — and what is still uncertain — about Lorfast, emphasizing that the research provides context but not individual predictions.

Key Studies & References

  1. Evidence-based pharmacological management of chronic neuropathic pain

Frequently Asked Questions (FAQ)

Common questions about Lorfast (FAQ)

Q: How quickly does Lorfast start working?

A: Official product information suggests that the antihistaminic effect typically begins within 1 to 3 hours after a dose is administered.

Q: Is Lorfast the same type of drug as Claritin?

A: Lorfast contains Loratadine as its active ingredient. This is the same active ingredient found in the brand-name medicine known as Claritin.

Q: Is there a generic version of Lorfast available?

A: Yes, the active ingredient in Lorfast, which is Loratadine, is widely available as an FDA-approved generic medication. This indicates that generic versions have been proven to be bioequivalent to the brand-name product.

Q: Is Lorfast a daily use medication or only for when symptoms appear?

A: Lorfast's administration schedule depends on the allergic condition being managed. It is used for short-term relief during short-term exposure, or as a daily regimen for extended periods, such as throughout an entire allergy season or for chronic hives.

Q: Is Lorfast considered effective for skin itching and hives?

A: The official indications for Lorfast include the relief of symptoms related to hives, which is also known as chronic idiopathic urticaria. This encompasses the mitigation of associated symptoms such as skin itching and redness.

Q: Can elderly patients take Lorfast?

A: The standard adult dose is generally used for elderly patients. Official documentation advises caution for older individuals with pre-existing liver or kidney impairment, which are conditions that typically necessitate a professional review for potential dosage adjustment.

Q: What safety category is Lorfast given for breastfeeding mothers?

A: According to authoritative summaries, loratadine and its active metabolite are known to pass into breast milk. However, due to the typically low levels found in milk, maternal use is not expected to cause adverse effects in breastfed infants. Official information generally advises caution.

Q: Are there any specific foods or drinks to avoid while taking Lorfast?

A: Official product information indicates that Lorfast may be consumed with or without food. Unlike some related medications, studies have found no known clinically significant interaction with common acidic fruit juices, such as grapefruit juice.

Q: Does Lorfast cause changes in appetite?

A: Official safety documentation classifies changes in appetite as an uncommon side effect, meaning it is reported in 0.1% to 1% of users. This change typically manifests as an increased appetite.

Q: Is Lorfast habit-forming or addictive?

A: Loratadine, the active component of Lorfast, is classified as a non-controlled substance. Official documents and regulatory status indicate that this medicine is not known to be habit-forming or addictive.

Q: Does Lorfast interfere with blood tests?

A: According to official information, Lorfast does not typically interfere with routine blood tests used for specific IgE allergy testing. However, Official guidance recommends that this medicine be discontinued for a period of about 5 days before a scheduled skin prick allergy test to avoid interfering with the results.

Q: Does Lorfast interact with commonly used over-the-counter pain relievers?

A: Official drug interaction studies indicate there are no known interactions between Loratadine and common over-the-counter pain relievers. This includes medicines such as ibuprofen and acetaminophen.

Q: Does Lorfast interact with blood pressure medication?

A: Official information suggests that the medicine is not typically associated with changes in blood pressure, and specific warnings regarding hypertension are generally absent from the single-ingredient product label.

Q: Does Lorfast interact with caffeine?

A: Single-ingredient Lorfast does not have a formal interaction with caffeine. However, product warnings advise a review of caution when taking combination products (such as Loratadine-D) that contain decongestants, as caffeine can enhance side effects like nervousness or a rapid heart rate.

Q: Does Lorfast interact with herbal supplements?

A: Definitive research on interactions between Lorfast and most herbal supplements is scarce. Official product information suggests that caution is appropriate, particularly with supplements that may also cause side effects like sleepiness or dry mouth.

Q: Are there any contraindications related to heart conditions and Lorfast?

A: Warnings related to heart conditions are generally associated with combination products containing decongestants, not typically with single-ingredient Lorfast.

Q: Is there a specific time of day that is best to take Lorfast?

A: There is no single best time of day specified in the regulatory guidance for taking this medicine, and it may be taken in the morning or the evening. Official guidance suggests that for continuous relief, it is beneficial to take the dose at approximately the same time each day.

Q: How long after stopping Lorfast will it be completely out of my system?

A: Due to the long elimination half-life of Lorfast and its active metabolite, desloratadine, it typically takes approximately 4 to 5 days after the final dose for the medicine to be completely cleared from the body.

Q: What is the purpose of the 'inactive ingredients' in Lorfast tablets?

A: The inactive ingredients listed in the product documents serve various pharmaceutical functions. These ingredients, which include fillers, binders, and coloring agents, ensure the correct size, stability, and disintegration speed of the tablet so that the medicine can work as intended.

How should Lorfast be stored and disposed of?

How to Store and Dispose of Lorfast? (Loratadine)

Official regulatory documents define the mandatory conditions for storing Lorfast to ensure its stability until the expiration date. The product must be stored below 25 C or 30 C (depending on the specific label) and kept in a dry place. It must be protected from both light and moisture, which requires keeping the medication in its tightly closed, original packaging.

Storage and Handling Requirements

Requirement Official Instruction
Temperature Store below 25 C / 30 C.
Protection Protect from light and moisture.
Safety Keep out of the reach and sight of children.

Disposal

Disposal instructions mandate that unused or expired Lorfast must be discarded in accordance with prevailing federal, state, and local regulations. General guidance advises against flushing medicines and recommends using authorized take-back programs when available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lorfast found in:

A-Z Index: